Document is current
Any future updates will be listed below
-
Authors
Russell, Stephen R. https://orcid.org/0000-0003-3776-1367
Drack, Arlene V.
Cideciyan, Artur V. https://orcid.org/0000-0002-2018-0905
Jacobson, Samuel G. https://orcid.org/0000-0003-2122-169X
Leroy, Bart P. https://orcid.org/0000-0002-9899-2081
Van Cauwenbergh, Caroline
Ho, Allen C. https://orcid.org/0000-0003-3921-608X
Dumitrescu, Alina V.
Han, Ian C.
Martin, Mitchell
Pfeifer, Wanda L.
Sohn, Elliott H.
Walshire, Jean
Garafalo, Alexandra V.
Krishnan, Arun K. https://orcid.org/0000-0002-3888-2614
Powers, Christian A.
Sumaroka, Alexander
Roman, Alejandro J. https://orcid.org/0000-0001-7368-3007
Vanhonsebrouck, Eva
Jones, Eltanara
Nerinckx, Fanny
De Zaeytijd, Julie https://orcid.org/0000-0003-4035-6389
Collin, Rob W. J.
Hoyng, Carel
Adamson, Peter
Cheetham, Michael E. https://orcid.org/0000-0001-6429-654X
Schwartz, Michael R.
den Hollander, Wilhelmina
Asmus, Friedrich
Platenburg, Gerard
Rodman, David
Girach, Aniz
-
Funding
Funding for this research was provided by:
ProQR Therapeutics, Inc
ProQR Therapeutics, Inc
ProQR Therapeutics, Inc
ProQR Therapeutics, Inc
Share holdings in ProQR Therapeutics, Inc
ProQR Therapeutics, Inc
ProQR Therapeutics, Inc
ProQR Therapeutics, Inc
- License Information
-
More Information
Article History
Received: 27 May 2021
Accepted: 18 February 2022
First Online: 4 April 2022
Competing interests
: S.R.R. and A.V.C. report grant funding from ProQR Therapeutics during the conduct of the study. A.V.D. reports grants and other from ProQR Therapeutics during the conduct of the study; personal fees from Medscape and Novartis; grants from Spark Therapeutics and the National Institutes of Health; a patent held by Novartis with royalties paid to Spark Therapeutics and a patent held by the University of Iowa issued to Spark Therapeutics, outside the submitted work. B.P.L. reports grants and non-financial support from ProQR Therapeutics; grants from the Fund for Research Flanders during the conduct of the study; grants from GenSight Therapeutics, IVERIC Bio and Vedere Bio; and grants and non-financial support from Novartis, Spark Therapeutics and RegenXBio, outside the submitted work. C.V.C. reports grants and non-financial support from ProQR Therapeutics, during the conduct of the study, and grants from GenSight Therapeutics, outside the submitted work. A.C.H. reports grants from ProQR Therapeutics both during the conduct of the study and outside the submitted work. E.J. reports grants and non-financial support from ProQR Therapeutics during the conduct of the study and grants from GenSight Therapeutics outside the submitted work. J.D.Z. reports grants from ProQR Therapeutics, during the conduct of the study, and grants from GenSight Therapeutics, outside the submitted work. R.W.J.C. reports other from ProQR Therapeutics, outside the submitted work, and a patent (antisense oligonucleotides) for the treatment of Leber congenital amaurosis licensed to ProQR Therapeutics. P.A. reports share holdings in ProQR Therapeutics. M.E.C. reports grants and personal fees from ProQR Therapeutics, during the conduct of the study, and grants and/or personal fees from Editas Medicine, BridgeBio, PYC and Alia Therapeutics, outside the submitted work. M.R.S., G.P. and A.G. are employees of ProQR Therapeutics. W.D.H., F.A. and D.R. are former employees of ProQR Therapeutics. S.G.J., A.V.D., I.H., M.M., W.P., E.H.S., J.W., A.V.G., A.K.K., C.A.P., A.S., A.J.R., E.V., F.N. and C.H. have nothing to disclose.
